Drug Trial Radar · NCT06128551
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
534
Planned (sponsor's estimate)
Start
Nov 14, 2023
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
Interventions
ElironrasibDrug
oral tablets
DaraxonrasibDrug
oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse events (AEs) in Phase 1bTime frame: Up to approximately 3 years
- Changes in vital signs in Phase 1bTime frame: Up to approximately 3 years
- Changes in clinical laboratory test values in Phase 1bTime frame: Up to approximately 3 years
- Dose Limiting Toxicities in Phase 1bTime frame: 21 days
- Changes in ECGs in Phase 1bTime frame: Up to approximately 3 years
- Overall Response Rate (ORR) in Phase 2Time frame: Up to approximately 3 years
Locations
56 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Withdrawn
UC IRVINE Health
Orange, California · Recruiting
UC Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Stanford Cancer Institute
Stanford, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Moffitt Cancer Center and Research Institute
Tampa, Florida · Recruiting
Community Health Network
Indianapolis, Indiana · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Cancer
Detroit, Michigan · Withdrawn
START Midwest
Grand Rapids, Michigan · Recruiting
Columbia University
New York, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Oklahoma
Oklahoma City, Oklahoma · Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania · Recruiting
Sarah Cannon Research Institue
Nashville, Tennessee · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Completed
MD Anderson
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Oncology San Antonio
San Antonio, Texas · Recruiting
START Texas
San Antonio, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
West Cancer Institute
Angers, France · Recruiting
Institut Bergonie
Bordeaux, France · Recruiting
Hospital Louise Pradel
Bron, France · Recruiting
Oscar Lambret Center of Lillle
Lille, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Cancer Institute of Montpellier
Montpellier, France · Recruiting
CHU Nantes
Nantes, France · Recruiting
Institute of Cancer of Strasbourg
Strasbourg, France · Withdrawn
Universitäts Klinikum Köln
Cologne, Germany · Recruiting
Klinikum Esslingen GmbH
Esslingen am Neckar, Germany · Recruiting
Krankenhaus Bethanien Moers
Moers, Germany · Recruiting
Klinkum Nurnberg Paracelsus Medical Unviersity
Nuremberg, Germany · Recruiting
Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle Marche
Ancona, Italy · Recruiting
Centro Di Riferimento Oncologico
Aviano, Italy · Recruiting
Institute Romagnolo per lo Studio Tumori
Meldola, Italy · Recruiting
Niguarda Cancer Center
Milan, Italy · Recruiting
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
Naples, Italy · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.